Clinical Trials Browser

Phase 1/2 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × amsonic acid × Clear all

NCT02923986 2020-05-28

Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

Phase 1/2 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute